1. Home
  2. SWAG vs HURA Comparison

SWAG vs HURA Comparison

Compare SWAG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stran & Company Inc.

SWAG

Stran & Company Inc.

HOLD

Current Price

$1.83

Market Cap

38.2M

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$1.90

Market Cap

87.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWAG
HURA
Founded
1994
2009
Country
United States
United States
Employees
N/A
19
Industry
Advertising
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
38.2M
87.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SWAG
HURA
Price
$1.83
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
37.0K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.41
52 Week High
$3.50
$4.41

Technical Indicators

Market Signals
Indicator
SWAG
HURA
Relative Strength Index (RSI) 50.94 66.77
Support Level $1.69 $1.56
Resistance Level $1.90 $2.68
Average True Range (ATR) 0.09 0.22
MACD 0.01 0.03
Stochastic Oscillator 72.73 69.31

Price Performance

Historical Comparison
SWAG
HURA

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: